ArrowMark Colorado Holdings LLC Has $8.87 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)

ArrowMark Colorado Holdings LLC decreased its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 2.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 345,048 shares of the company’s stock after selling 9,927 shares during the period. ArrowMark Colorado Holdings LLC owned 0.37% of NewAmsterdam Pharma worth $8,868,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. National Bank of Canada FI acquired a new stake in NewAmsterdam Pharma during the 4th quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth $80,000. Barclays PLC raised its stake in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after buying an additional 7,199 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in NewAmsterdam Pharma in the fourth quarter valued at $154,000. Finally, The Manufacturers Life Insurance Company bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at $221,000. 89.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on NAMS. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a research note on Monday, March 3rd. Needham & Company LLC restated a “buy” rating and set a $42.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. HC Wainwright reiterated a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Finally, Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $43.33.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper bought 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the acquisition, the director now directly owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. This trade represents a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 19.50% of the stock is owned by insiders.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $20.03 on Friday. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $27.29. The firm has a market capitalization of $2.20 billion, a PE ratio of -7.70 and a beta of -0.01. The firm has a fifty day simple moving average of $19.68 and a two-hundred day simple moving average of $21.24.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. On average, equities analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.